<DOC>
	<DOCNO>NCT01690468</DOCNO>
	<brief_summary>The main purpose study determine Triciribine ( TCN ) carboplatin safe tolerable give together , determine combination drug help people recurrent ovarian cancer .</brief_summary>
	<brief_title>PTX-200 Carboplatin Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>At least 18 year age Histologically confirm , measurable nonmeasurable , recurrent persistent , platinumresistant epithelial ovarian , fallopian tube primary peritoneal carcinoma . By standard Gynecologic Oncology Group ( GOG ) criterion , platinumresistant disease define diseasefree interval le 6 month follow treatment platinumbased regimen , progression disease platinumbased therapy . At least one prior regimen chemotherapy , maximum number chemotherapy cycle A serum creatinine ≤ 1.5 mg % obtain ≤ 2 week prior entry Adequate hematologic reserve obtain ≤ 2 week prior entry : leukocytes ≥ 3,000 mm^3 ; absolute neutrophil count ≥ 1500 mm^3 ; platelet ≥ 100,000 mm^3 Adequate hepatocellular function : aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) ≤ 3x upper limit normal within institutional limit ; bilirubin ≤ 1.5 mg/dl Gynecologic Oncology Group ( GOG ) Performance Status 0 , 1 , 2 Life expectancy least 90 day The patient chemotherapy , biologic therapy radiation 28 day . Neuropathy ( sensory motor ) less equal grade 1 per Common Toxicity Criteria ( CTC ) version 4 Prior TCNPM therapy History allergic reaction attribute compound similar chemical biologic composition TCNPM Patients must diseasefree prior invasive malignancy &gt; 2 year exception basal cell squamous cell carcinoma skin . Inability give inform consent Pregnancy Corrected QT interval ( QTc ) prolongation &gt; 450 millisecond ( msec )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>